TOP2B
protein-codingDNA topoisomerase II beta, the group of Topoisomerases
Gene summary
This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, beta, is localized to chromosome 3 and the alpha form is localized to chromosome 17. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2016]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~66.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0012243
Submitter: ClinGen
TOP2B was first reported in relation to autosomal dominant B-cell immunodeficiency, distal limb anomalies, and urogenital malformations in 2019 (Broderick L, et al., 2019, PMID: 31409799). Dominant negative mutations in the TOP2B gene, encoding DNA topoisomerase 2-beta, cause Hoffman syndrome (also known as BILU syndrome) with humoral b-cell immunodeficiency, distal limb anomalies, dysmorphic facial features, and urogenital malformations. Three missense variants and one in-frame deletion in the TOPRIM domain have been reported in six probands, and three additional family members, in three publications (PMIDs: 31409799, 32128574, and 33459963). This gene-disease association is supported by its function, generating transient double-stranded DNA breaks that alleviate negative supercoils (PMID: 10684600). Failure to relax topological stress in patient cells (PMID: 32128574) can reduce the production of multiple gene products, and cause loss of function of large genes, which are most vulnerable to topologic stress. Many B-cell-specific transcription factor genes are relatively long and require TOP2B for efficient transcription, suggesting a pathogenesis mechanism for the TOP2B mutations and the role of TOP2B in B-cell development (PMID: 31409799). Additionally, there are b-cell specific knockout and knock-in mouse models that recapitulates disease (PMID: 31409799). In summary, there is moderate evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship.
Inheritance Pattern: AD
Disease ID:MONDO:0700092
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0012243
Submitter: Illumina
Inheritance Pattern: AD
Disease ID:MONDO:0012243
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0012243
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0012243
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious; Craniofacial; Genitourinary; Musculoskeletal
Intervention: Allergy/Immunology/Infectious
Rationale: Among other features, the condition can involve susceptibilty to infections, and awareness may allow preventative measures and early and aggressive treatment of infections
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to TOP2B variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001330700.2. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | 231 | 10 | 248 | ||
| missense | 2 | 4 | 496 | 26 | 1 | 529 |
| nonsense | 1 | 10 | 11 | |||
| start loss | 1 | 1 | ||||
| frameshift | 15 | 1 | 16 | |||
| splice donor/acceptor (+/-2bp) | 13 | 1 | 14 | |||
| Total | 2 | 5 | 542 | 258 | 12 | 819 |
Highest pathogenic variant AF is 0.00004984122
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001317629.1 | 36 | MANE Select | |
| Ensembl | ENSP00000264331.4 | 36 | MANE Select | |
| RefSeq | NP_001059.2 | 36 | Standard | |
| Ensembl | ENSP00000388216.1 | 2 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| top2b | Danio rerio | Structure: retinal bipolar neuron Quality: morphology abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Doxorubicin Pathway (Cardiomyocyte Cell), Pharmacodynamics
- Etoposide Pathway, Pharmacokinetics/Pharmacodynamics
- Etoposide Action Pathway
- Etoposide Metabolism Pathway
- Post-translational protein modification
Biological Process
- resolution of meiotic recombination intermediates
- sister chromatid segregation
- neuron migration
- DNA topological change
- axonogenesis
Molecular Function
- DNA binding
- chromatin binding
- DNA topoisomerase type II (ATP-hydrolyzing) activity
- protein kinase C binding
- ATP binding
Cellular Component
- heterochromatin
- nucleus
- nucleoplasm
- nucleolus
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000435706
- Coding exons
- 36
- Length
- 66924
- Individuals with no LoFs
- 124626
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 26
- Defined
- 124652
- p
- 0.000104
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 3.86 | 474 | 777 | 0.610 | 0.0000383 | 10705 |
| Missense (PolyPhen) | 53 | 212.73 | 0.24914 | 2820 | ||
| Synonymous | 0.865 | 245 | 263 | 0.932 | 0.0000130 | 2891 |
| Loss of Function | 6.97 | 12 | 78.8 | 0.152 | 0.00000401 | 1131 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000065 | 0.000065 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00057 | 0.00050 | rare |
| Finnish | 0.00019 | 0.00019 | rare |
| European (Non-Finnish) | 0.000063 | 0.000062 | rare |
| South Asian | 0.00013 | 0.00013 | rare |
| Other | 0.00017 | 0.00017 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. {ECO:0000269|PubMed:10684600}.;
- Disease
- DISEASE: Note=A defect in TOP2B is associated with autism spectrum disorder (ASD). {ECO:0000269|PubMed:28343847}.;
Recessive Scores
- pRec
- 0.375
Intolerance Scores
- LoFtool
- 0.820
- RVIS EVS
- -0.15
- RVIS percentile EVS
- 42.28
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.878
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |